Cobrotoxin from Naja naja atra Venom Ameliorates Adriamycin Nephropathy in Rats

作者: Qi Zhu , Jian-qun Kou , Zheng-Hong Qin , Shu-Zhi Wang , Yin-li Xu

DOI: 10.1155/2015/450581

关键词:

摘要: Chronic kidney disease (CKD) becomes a global health problem with high morbidity and mortality. Adriamycin- (ADR-) induced rodent chronic nephropathy is classic experimental model of human minimal lesion nephrotic syndrome. The present study investigated the effect cobrotoxin (CTX) on ADR-induced nephropathy. Rats were given 6 mg/kg ADR once through tail vein to replicate model. CTX was administered rats daily by placing fast dissolving membrane strip under tongue starting from 5 days prior administration until end experiment. results showed that ameliorated symptoms syndrome reduced body weight loss, proteinuria, hypoalbuminemia, dyslipidemia, serum electrolyte imbalance, oxidative stress, renal function abnormities, pathological lesions. Anti-inflammatory cytokine IL-10 expression elevated after in inhibited phosphorylation IκB-α NF-κB p65 nuclear translocation. Meanwhile, upregulated protein level podocyte-specific nephrin downregulated fibrosis-related TGF-β. These findings suggest may be potential drug for diseases.

参考文章(51)
Mi Hee Park, Ho Seub Song, Ki Hyun Kim, Dong Ju Son, Seung Ho Lee, Do Young Yoon, Youngsoo Kim, Il Young Park, Sukgil Song, Bang Yeon Hwang, Jae Kyung Jung, Jin Tae Hong, Cobrotoxin inhibits NF-κB activation and target gene expression through reaction with NF-κB signal molecules Biochemistry. ,vol. 44, pp. 8326- 8336 ,(2005) , 10.1021/BI050156H
Yin-Li Xu, Jian-Qun Kou, Shu-Zhi Wang, Cao-Xin Chen, Zheng-Hong Qin, Neurotoxin from Naja naja atra venom inhibits skin allograft rejection in rats International Immunopharmacology. ,vol. 28, pp. 188- 198 ,(2015) , 10.1016/J.INTIMP.2015.05.040
Zheng Hong Qin, Jing Kang He, Rong Han, Yan Xie, Gui Li Dai, Lu Jia Zhu, Therapeutic potential of Naja naja atra venom in a rat model of diabetic nephropathy. Biomedical and Environmental Sciences. ,vol. 25, pp. 630- 638 ,(2012) , 10.3967/0895-3988.2012.06.004
Oktay Tacar, Pornsak Sriamornsak, Crispin R. Dass, Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems Journal of Pharmacy and Pharmacology. ,vol. 65, pp. 157- 170 ,(2012) , 10.1111/J.2042-7158.2012.01567.X
VINCENT WS LEE, DAVID CH HARRIS, Adriamycin nephropathy: A model of focal segmental glomerulosclerosis Nephrology. ,vol. 16, pp. 30- 38 ,(2011) , 10.1111/J.1440-1797.2010.01383.X
Raymond B. Weiss, The anthracyclines: will we ever find a better doxorubicin? Seminars in Oncology. ,vol. 19, pp. 670- 686 ,(1992) , 10.5555/URI:PII:009377549290036Z
Ilker Cöven, Faik Ilik, Mustafa Kemal Ilik, Levatiracetam for the management of Lance-Adams syndrome Iranian journal of child neurology. ,vol. 8, pp. 57- 59 ,(2014) , 10.22037/IJCN.V8I2.3622
Gaetano Bacci, Stefano Ferrari, Franco Bertoni, Pietro Ruggieri, Piero Picci, Alessandra Longhi, Roberto Casadei, Nicola Fabbri, Cristiana Forni, Michela Versari, Mario Campanacci, Long-Term Outcome for Patients With Nonmetastatic Osteosarcoma of the Extremity Treated at the Istituto Ortopedico Rizzoli According to the Istituto Ortopedico Rizzoli/Osteosarcoma-2 Protocol: An Updated Report Journal of Clinical Oncology. ,vol. 18, pp. 4016- 4027 ,(2000) , 10.1200/JCO.2000.18.24.4016
Jack Lawson, Jonathan Elliott, Caroline Wheeler-Jones, Harriet Syme, Rosanne Jepson, Renal fibrosis in feline chronic kidney disease: known mediators and mechanisms of injury. Veterinary Journal. ,vol. 203, pp. 18- 26 ,(2015) , 10.1016/J.TVJL.2014.10.009
Sandra Merscher, Christopher E. Pedigo, Armando J. Mendez, Metabolism, energetics, and lipid biology in the podocyte - cellular cholesterol-mediated glomerular injury Frontiers in Endocrinology. ,vol. 5, pp. 169- 169 ,(2014) , 10.3389/FENDO.2014.00169